Eli Lilly: clinical data flows in migraine and diabetes

(CercleFinance.com) - Eli Lilly will present phase 3 data for two investigational, non-opioid treatments for migraine at the upcoming American Headache Society (AHS) annual meeting in San Francisco.


The US drugmaker will present late-breaking data for the once-monthly antibody galcanezumab from the largest preventive trial conducted in episodic cluster headache to date.

The group also plans to unveil post-hoc analysis from three Phase 3 studies evaluating galcanezumab for the prevention of migraine in patients who previously failed treatment with Botox.

Galcanezumab is a currently under review by the US Food and Drug Administration (FDA) for the prevention of migraine in adults. A decision is expected by the end of September 2018.

In addition, Phase 3 data evaluating investigational, oral, first-in-class moleculelasmiditan for the acute treatment of migraine will be featured at a platform presentation.

Eli Lilly also presented numerous data at American Diabetes Association scientific sessions over the weekend, including clinical results showing that Jardiance reduced risk of kidney disease progression in adults with type-2 diabetes and established cardiovascular in adults with cardiovascular disease and type-2 diabetes.



Copyright (c) 2018 CercleFinance.com. All rights reserved.